Bret Jensen

Dynavax Technologies Corporation revenue boosted from Covid pandemic, but this has now nearly completely diminished. Find out why DVAX stock is a Buy.

Analyst firms are optimistic about Pliant Therapeutics’ potential, and the company has over $500m in cash on its balance sheet. Read more on PLRX stock here.

Longboard Pharmaceuticals, Inc. shares have surged in 2024 due to positive mid-stage trial data. Click here for more on the LBPH stock prospects.

NeoGenomics is making progress in sales growth and reducing losses, but potential litigation concern for 2024. Read more to see a full analysis of NEO stock.

Collegium Pharma has been paying down debt and repurchasing stock with its impressive operational cash flow. Read more to see my updated analysis on COLL stock.

The CRE market is seeing fast rising delinquency rates, especially for loans against office properties. Read why CRE issues will impact REITs and regional banks.

CRE market is seeing fast rising delinquency rates, especially for loans against office properties. Read why CRE issues will impact REITs and regional banks.

Sana Biotechnology’s shares rose some 60% since secondary offering in Feb., driven by positive early clinical and research results. Find out why SANA stock is a Sell.

Biotech M&A activity surged at the end of 2023, which helped small biotech sector surge. Find out 3 logical buyout targets in biotech/biopharma space in 2024.

Commercial real estate markets continue to experience deterioration, leading to rising default rates amid record office vacancy rates. Read more details here.